TrialInvestigational new drugs2013

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Darren R Feldman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.